Mederi CE marks second-gen Secca and Stretta systems
This article was originally published in Clinica
Mederi Therapeutics has CE marked its second-generation Stretta and Secca systems for sale in Europe. Stretta, a therapy for gastroesophageal reflux disease, involves insertion of the Stretta catheter through the patient’s mouth and into the valve between the stomach and oesophagus. Radiofrequency energy is delivered to the lower oesophageal sphincter and gastric cardia to create small thermal lesions. When these lesions heal, the tissue contracts, narrowing the opening to the oesophagus and preventing reflux. The Secca system is designed to treat bowel control disorder, or BCD. It uses a similar technique to contract the anal sphincter. These latest versions of the systems have an improved interface, are easier to use, and are smaller, lighter, and highly portable, the Greenwich, Connecticut firm says.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.